NexImmune Reports First Quarter 2021 Financial Results and Recent Updates

NEXT STORY
CohBar Reports First Quarter 2021 Financial Results and Provides Business Update
PREV STORY
Sandoz Canada launches its 6th biosimilar with Inclunox® and Inclunox® HP (Enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (High Potency))
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Longest Follow-Up Data on Trastuzumab Biosimilar Presented at 2021 SABCS

author_avatar
NASDAQ Market News

Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection

author_avatar
NASDAQ Market News

MorphoSys to Raise Capital via a Private Placement of New Shares

Martinsried / Munich, Germany, Nov. 15, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt Stock ...

author_avatar
NASDAQ Market News